GSK: EU Approves Vaccine For Respiratory Virus

According to GlaxoSmithKline (GSK) on Wednesday, the European Commission has approved its vaccine as the world’s first-ever vaccine for the Respiratory Syncytial Virus, to be used by adults aged 60 and over.

“This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time,” GSK’s chief scientific officer Tony Wood said in a statement.

The United States approved the drug last month, while the vaccine is the culmination of a decades-long hunt to protect vulnerable people from the common illness.

Read Also: Drugmaker GSK Says EU To Review Womb Cancer Treatment

RSV normally causes mild, cold-like symptoms, but can be serious for infants and the elderly, as well as those with weak immune systems and underlying conditions.

In severe cases, it can cause pneumonia and bronchiolitis, an inflammation of the small airways deep inside the lungs.

Analysts predict the market could be worth over $10 billion in the next decade, with similar shots from other makers including Pfizer and Moderna expected to follow soon.

RSV is “a common, contagious respiratory virus that leads to approximately 20,000 in-hospital deaths each year in adults aged 60 years and over in Europe”.